Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto®, a biosimilar to the reference product Enbrel® (Etanercept), in Australia. Nepexto® will be promoted by Generic Health, its local partner and a leading provider of high-quality generic prescription, injectable and over-the counter medicines, to expand access to patients in Australia.
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Since receiving EU marketing authorization in 2020, Nepexto® has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto® into new markets worldwide and further strengthen the company's immunology offering.
Nepexto will be promoted by Generic Health, BBL’s local partner and a leading provider of high-quality generic prescription, injectable and over-the-counter medicines, to expand access to patients in Australia.
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe.
Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is working towards expanding Nepexto into new markets worldwide and further strengthen the company’s immunology offering.
Biocon Biologics, a subsidiary of Biocon, is a fully integrated, global biosimilars company. It has commercialized various biosimilars in key emerging markets and advanced markets. It has a pipeline of numerous biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases.
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.
The company’s consolidated net profit surged 154.2% to Rs 344.50 crore on a 12.8% jump in net sales to Rs 4,358.10 crore in Q4 FY25 over Q4 FY24.